Beyond mutations.
Towards functional precision.
Unlocking therapeutic targets with patient-derived organoids and high-throughput functional genomics.
Product Advantages
The era of precision medicine has arrived, the limitations of traditional detection methods in tumor drug matching have led to the treatment needs of many patients not being fully met. TRICBIO is based on the TRiC technology platform high-throughput tumor target sensitivity assay, it provides more comprehensive, accurate and efficient solutions for cancer patients and clinicians.
High-throughput target sensitivity detection of TRICBIO organisms detect drug target function directly in patient tumor primary samples, a breakthrough has been achieved.
• Comprehensiveness: Covering more than 1600 targeted drugs and more than 200 drug targets on the market.
• Leadership: A comprehensive assessment can be achieved with a single test, covering a wider range than traditional methods.
• Accuracy: Consistent with the real tumor microenvironment, providing more reliable drug matching information.
Comprehensive Coverage
The only functional testing product on the market that covers all commercially available oncology drugs, empowering patients with multi-dimensional treatment strategies.
Efficient and Fast
Results for functional target analysis are delivered within two weeks of sample submission, with drug sensitivity testing completed in three weeks, rapidly securing critical treatment time for patients.
Accurate Matching
Directly detect the function of drug targets to ensure high consistency between test results and actual clinical treatment.
Personalized drug susceptibility testing based on the organoid 1.0 model and the organoid 2.0 model, we establish our own mini-tumor for each tumor patient, screen a variety of tumor drugs and radiotherapy sensitivity on this basis, and establish each patient's chemotherapy, immunotherapy, targeted drug and radiotherapy sensitivity files to provide data support and guidance for personalized tumor treatment.
Tumor Organoids 1.0
Based on ALI PDO (organoid 2.0) culture to construct an organoid model, and screen the best solution in different targeted and immune combination regimens.
Organoid 2.0 increases the anti-PD-L1/PD-L1 of testing targeted immunity compared to organoids 1.0, anti-CTLA4 and screening for the effectiveness of drugs such as anti-EGFR targeting vascular epithelial cells. The scope of clinical use is more extensive, with great clinical guidance value!
TRICBIO, Leading New Changes in Tumor Precision Medication
Tumor Organoids 2.0
For customized research/target development services, please contact TRICBIO Team. We will provide you with professional, efficient and reliable one-stop support.
Seamless Access
Seamlessly integrates with surgical procedures, needle biopsies, and other clinical workflows, ensuring safe and efficient operations.
From 1.0 to 2.0: Ushering in a New Era of Personalized Tumor Drug Sensitivity Testing
Functional Precision, Bridging the Future of Medicine
